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1 Executive Summary
Aflibercept is an anti-vascular endothelial growth factor (anti-VEGF) drug used to treat several retinal
diseases such as macular degeneration. It accomplishes this by binding and inhibiting VEGF, which is the
growth factor that is responsible for abnormal blood vessel growth. Overexpression of VEGF can lead
to interference with the macula, and subsequent vision loss. Aflibercept is prescribed to treat macular
degeneration due to VEGF overexpression. It is administered via intravitreal injection. Analysis of the
transport of aflibercept through the vitreous humor is critical to understanding whether or not patients are
receiving appropriate amounts of drug at the macula boundary, where the abnormal growth of blood vessels
is contributing to macular degeneration. This study will assess if if the current market dose of aflibercept is
successfully inhibiting VEGF for an appropriate time period.
The scope of analysis involved construction of a three-dimensional geometry of the vitreous humor in
COMSOL, an implementation of physical properties and parameters of the vitreous humor and aflibercept,
an illustration of key results, a sensitivity analysis on certain parameters, and a validation of the COMSOL
implementation.
The analysis was conducted for a 3D diffusion problem, coupled with convection. Convection is due
to pressure-driven flow, a result of the inherent pressure difference in the vitreous humor. Degradation
or inactivation of aflibercept was also considered by modeling the second-order binding of aflibercept to
VEGF.
The distribution of aflibercept throughout the vitreous humor was successfully determined. Due to
asymmetry in the injection site, or the placement of drug, it was found that the distribution of drug is asym-
metric at early times, and becomes more uniform at later times. A similar result was found at the macula
boundary, which is the target area of interest for this study. It was also shown that VEGF concentration is
successfully inhibited upon the introduction of aflibercept. Based on the model, VEGF began to accumulate
after initial suppression within 20 to 40 days of aflibercept injection. This coincides with the recommended
interval between aflibercept injections, which is 28 days.
Improvements in future model implementation could provide a result that more accurately represents the
transport of aflibercept in the eye. These improvements include implementing an initial injection velocity
when aflibercept is introduced, and the use of a more realistic geometry, such as an MRI scan, to build the
geometry in the COMSOL model.
2 Introduction
A suite of retinal diseases, namely, 1) wet age-related macular degeneration, 2) diabetic macular edema,
3) diabetic retinopathy, and 4) macular edema following retinal vein occlusion, may be treated with afliber-
cept, an FDA-approved anti-VEGF prescription medication. The medium through which aflibercept is
transported is the vitreous humor, a gelatinous body with well-studied properties. However, differing con-
centrations of aflibercept can have varying effects on the human eye. The ability to model such transport
could help determine optimal levels of aflibercept for treatment of a multitude of retinal diseases. For proper
treatment of many retinal diseases, the concentration of the treatment molecule must be kept at a constant
level. Like other forms of macular treatment, aflibercept also degrades within the eye and the ability to
model concentrations, as well as transport in three-dimensional space, is definitely advantageous. This
will allow for optimization of drug injection as well as the minimization of injections, which itself can have
many problems for the patient including optical discomfort and physical damage from the injection process.
Such a model could also be useful in augmenting the drug development process by reducing dependence on
clinical trials, which can be costly and invasive, due to the necessary injection of drug in the eye.
Several studies have delved into the nature of aflibercept administration and its optimal usage. Ohr and
Kaiser’s study of aflibercept injection on macular degeneration determined that dosages of 2 mg and 4 mg
have proven to have significant improvement in vision at 8 week injections over 12 months. Aflibercept
was the drug of choice as compared to other drugs used to treat retinal diseases, because it had a longer
half-life within the eye as well as a higher binding affinity to VEGF. A variety of other studies have reported
results on the geometry and the specific quantities of permeability and diffusivity of the eye. Other studies
have modeled drug transport within the intravitreal fluid and have determined that the transport has both
convective and diffusive components.
Current studies on treatment of macular degeneration have included three-dimensional coupled convective-
diffusive transport of drugs through the usage of an implant that released drug at specified intervals [8].
Other studies include two-dimensional modeling of intravitreal injections within the eye with no adherence
1
to any single drug nor any vitreous substitutes [5]. Lastly, three-dimensional modeling specifically for
aflibercept transport has not been done.
This study modeled aflibercept transport in three-space to address the need for three-dimensional in-
travitreal studies that are lacking in literature. It was also designed as a method to verify aflibercept effec-
tiveness, with the hope of reducing dependence on clinical trials that can be costly and invasive. The model
focused on the effects of diffusion, convection, and degradation on aflibercept transport, and the subsequent
effects on VEGF.
2.1 Problem Statement
The purpose of this research was to model the transport of aflibercept in the vitreous humor and to
analyze the effects of aflibercept on VEGF concentration over time. By doing so, it can be determined if
aflibercept is inhibiting VEGF for a long enough time period. The model was constructed as a 3D diffusion
problem, coupled with convection. This convection is due to pressure driven flow, which results from a
pressure gradient within the vitreous humor. Degradation and production terms were also considered for
both aflibercept and VEGF.
2.2 Design Objectives
The primary goal of this model was to determine if the current market concentration of aflibercept is
sufficiently inhibiting VEGF for an appropriate time period. A COMSOL model was used to illustrate
the distribution of drug throughout the vitreous humor, and analyze the effects of aflibercept on VEGF
accumulation. The geometry, dimensions, and physical properties of the human eye were implemented into
the COMSOL model. The following objectives were completed during the process of this study:
1. Constructed a 3D model in COMSOL that illustrates the geometry, dimensions, and physical proper-
ties of the human eye
2. Assessed the distribution of aflibercept throughout the vitreous humor over time, in addition to the
distribution of aflibercept at the macula boundary over time
3. Identified parameters that have a large impact on aflibercept concentration at the macula boundary
4. Checked the validity of the model, with respect to aflibercept half-life in the vitreous humor, by
comparing with literature
5. Determined the effects of aflibercept on VEGF concentration over time
3 System Geometry
Constructing a model in COMSOL requires proper implementation of geometry. Dimensions for the
model constructed in COMSOL are taken from actual measurements of the human eye [2]. Assumptions
were made where appropriate to simplify the model and reduce the total amount of computation needed.
Such assumptions are discussed in section 3.2.
3.1 Physical Problem
In this study, the transport of aflibercept in the vitreous humor was modeled. Aflibercept is placed into
the vitreous humor via intravitreal injection. Considering the eye to be oriented so that the pupil is facing
upwards (Figure 1), a typical intravitreal injection site is located 3.5 mm posterior to the limbus and 5.5
mm to either the left or right of the pupil axis [12][2] (Figure 2). The injection site was modeled as a sphere
with a radius of 2.285 mm, which was determined from the recommended dosage volume of 0.5 mL [1]
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Figure 1: Illustration of the human eye during the intravitreal injection process. Drug is injected into the
vitreous humor and transported throughout the eye through diffusion and pressure driven flow. The target
area for aflibercept, an anti-VEGF drug, is a region of abnormal blood vessels adjacent to the macula that
result from overexpression of VEGF.
Three-dimensional drug diffusion was modeled for aflibercept once it was injected into the vitreous
humor. Aflibercept was modeled with first order metabolism and second order inactivation, due to the for-
mation of an aflibercept-VEGF complex. Drug diffusion was coupled with convection, which is illustrated
by Darcy’s Law, and is caused by an inherent pressure gradient between the anterior hyaloid membrane and
the posterior retina.
3.2 Schematic
The physical problem described in section 3.1 was converted to a schematic that could be used to
construct the COMSOL model. Dimensions of the human eye, found in literature, were used to design the
schematic (Table 1). Where appropriate, assumptions were made to simplify the model and reduce the total
amount of computation needed.
Table 1: Dimensions of the human eye. Each value was found in literature and implemented in the geometry
of the COMSOL model, as shown in Figure 2.
Dimension Value (mm) Source
Anterior hyaloid membrane radius 5.5 [2]
Distance between limbus and injection site 3.5 [12]
Radius of spherical injection site 2.285 [1]
Radius of vitreous humor 11 [2]
Distance between macula boundary and retina 0.425 [13]
Diameter of macula 5.5 [13]
The eye was assumed to be a perfectly round sphere, with a uniform radius in all directions. The lens
of the eye, however was not considered in the schematic due to its impermeability. This is shown as a zero
flux boundary condition at the anterior hyaloid membrane (denoted in red) which is approximated as a plane
parallel to the surface of the pupil.
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Figure 2: Schematic of the physical problem. Dimensions of the human eye, as found in literature, are
indicated on the schematic. Boundary and initial conditions are also shown. There is no mass flux at the
hyaloid membrane, shown in red. Throughout the retinal surface, shown in blue, there is an outwards flux
condition, referred to as retinal clearance. The placement of drug in the vitreous humor after intravitreal
injection is modeled as a small sphere with radius radius, rs, and with initial concentration, cAi.
Specified boundary and initial conditions are shown in Figure 2. For more information on boundary
and initial conditions, see section 5. At the hyaloid membrane (denoted in red) there is no flux. However,
throughout the retinal surface (denoted in blue) there is an outwards flux condition, described in literature
as retinal clearance [5]. The injected drug is modeled as a sphere of radius, rs, with an initial concentration,
cAi.
An additional schematic was designed to illustrate pressure-driven flow in the vitreous humor (Figure
3). Pressure-driven flow results from an inherent pressure gradient between the anterior hyaloid membrane
and the posterior retina [5].
Figure 3: Additional schematic to show pressure-driven flow in the vitreous humor. Pressure difference
between the anterior hyaloid membrane and the posterior retina results in flow. The velocity that results
from this flow is calculated using Darcy’s Law.
Higher pressure is exhibited at the anterior hyaloid membrane and lower pressure is exhibited at the pos-
terior retina [5]. This difference in pressure results in flow within the vitreous humor towards the posterior
retina. This pressure-driven flow is implemented in the model using Darcy’s Law (see section 4).
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4 Governing Equations
The physics of the problem needs to be described in the form of governing equations. This model uses
governing equations for two species: aflibercept and VEGF. Listed below are equations that govern the
transport, degradation, and production of aflibercept and VEGF.
Equation 1 is the governing equation for aflibercept transport.
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It contains a transient term, a convective term, a diffusive term, a second order inactivation term, rV ,
and a first order metabolism term, rA. Velocities, u, in the convective term are calculated using Darcy’s Law
(Equation 6). The diffusion term is governed by the diffusion coeffient, DA.
The governing equation for VEGF is given by Equation 2.
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Similar to the aflibercept governing equation, the governing equation includes a transient term, a con-
vective term, a diffusive term, and a second order inactivation term. Velocities, obtained from Darcy’s Law
(Equation 6), are calculated in the same way as for Equation 1. The diffusion term for VEGF is governed
by the diffusion coefficient, DV .
The inactivation term, rV , which depends on both the concentration of free aflibercept, cA, and VEGF,
cV , is defined by Equation 3 with a second order rate constant, kV .
rV =−kV · cA · cV (3)
This second order inactivation is due to the formation of an aflibercept-VEGF complex, which essen-
tially renders both species inactive. The inactivation term, rV , is present in both Equation 1 and Equation 2.
This is because both aflibercept and VEGF are involved in forming the aflibercept-VEGF complex.
The first order metabolism term, rA, is defined by Equation 4 and contains the first order rate constant
kA.
rA =−kA · cA (4)
Equation 4 describes the degradation of aflibercept in the vitreous humor. No studies have been conducted
on the exact mechanicisms of aflibercept metabolism but is expected to undergo metabolism via proteolysis
[1]
Zeroth order production of VEGF, rP, is considered in the model and is governed by the rate constant,
kP.
rP = kP (5)
Rate constants and parameters specified in the governing equations are discussed further in section 6.
Darcy’s Law is implemented in the model at steady-state.
u=−K
µ
∇P (6)
Darcy’s Law requires the following properties: permeability, K, vitreous humor viscosity, µ , and pres-
sure gradient, ∇P.
5 Boundary and Initial Conditions
Boundary and initial conditions are a necessary part of any mass transfer problem. Without them, it
is impossible to find particular solutions within a domain for a given governing equation. The following
boundary and initial conditions (Table 2) were found in literature and implemented in the COMSOL model.
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Table 2: Boundary and Initial Conditions. Conditions that needed to be implemented in the model to solve
the governing equations were found in literature. See the following text in section 5 for explanations of
these conditions. For more details on the flux at the retina boundary, see section 6.
Boundary Condition Value Units Source
Flux at hyaloid membrane 0 molm2·s [5]
Flux at the retina boundary R · cA molm2·s [5]
Pressure at hyaloid membrane 15.09375 Pa [5]
Pressure at vitreous humor 14.90625 Pa [5]
Initial drug concentration in vitreous humor 0 molm3 N/A
Initial drug concentration in injection site 40 mgmL [1]
Initial drug concentration in injection site 0.34783 molm3 [1]
Initial VEGF concentration 1.3122 ·10−7 molm3 [9]
Initial pressure in vitreous humor 15 Pa [5]
Boundary conditions of the vitreous humor domain, including flux at the hyaloid membrane, flux at the
retina boundary, and pressure gradient in the eye, are adapted from models on two-dimensional intravitreal
transport [5]. Pressure values were calculated to account for the 1.25% pressure drop in the vitreous humor.
An average pressure of 15 Pa, as noted by Ferreira et al., was used as the mean pressure in the vitreous
humor [5]. A 0.625% pressure difference between the vitreous humor and the posterior retina, and a 0.625%
pressure difference between the anterior hyaloid membrane and the vitreous humor, were calculated, then
subtracted from and added to the mean pressure, respectively. Initial drug concentration was obtained from
the Eylea Full Prescribing Information (Regeneron Pharmaceuticals, Inc.). Initial VEGF concentration was
obtained from Nonobe et al [9].
6 Input Parameters
Input parameters are also required to solve governing equations for mass transport. Like boundary and
initial conditions, parameters are obtained from literature and implemented in the COMSOL model (Table
3).
Table 3: Input parameters. Justifications for each of the parameters chosen are explained in the following
text and supported by sources.
Parameter Symbol Value Units Source
Drug diffusion coefficient DA 5.556 ·10−10 m2s [5]
VEGF diffusion coefficient DV 1.42 ·10−10 m2s [7]
Second order inactivation rate constant kV 410 ·10−5 1M·s [10]
First order metabolism rate constant kA 149.26 ·10−9 1s [6]
Zeroth order production rate constant kP 1.22 ·10−14 Ms [11]
Permeability in vitreous humor K 10 ·10−17 m2 [4]
Vitreous humor viscosity µ 1 ·10−3 Pa · s [5]
Retinal clearance R 1 ·10−9 ms [5]
Drug diffusion coefficient for aflibercept, DA , was adapted from that of dexamethasone, an intravitreal
corticosteroid [5]. VEGF diffusion coefficient, DV , was obtained from Hutton-Smith et al [7].The second
order inactivation rate constant, kV , describes the binding of aflibercept and VEGF to form an aflibercept-
VEGF complex. This value was obtained from Papadopoulos et al.[10]. Aflibercept degradation in the eye
is governed by a first order metabolism rate constant, kA , which was obtained from Finley et al. [6] VEGF
production in the eye is governed by a zeroth order production rate constant, kP [11]. Permeability in the
vitreous humor, K, was derived from an intrinsic permeability value for meat [4]. The vitreous humor was
treated as a permeating fluid with viscosity, µ [5]. Retinal clearance, R, is defined as the rate of clearance
of drug at the retina boundary. This was implemented into the flux boundary condition at the retina (see
section 5), which states that flux is dependent on concentration at the boundary [5].
7 System Discretization
In a computational software such as COMSOL, computations are only performed at certain nodes within
the domain. To obtain values at different locations within the domain that are not nodes, interpolations are
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performed. Error that results from interpolations is known as discretization error. To minimize this error,
a more refined mesh could be used. However, more refined meshes require more computational time. The
method for determining mesh is described in section 7.2.
7.1 Mesh
A mesh was defined for the system geometry in COMSOL (Figure 4).
Figure 4: A user-defined mesh for the system geometry in COMSOL. The mesh configuration is given in
Table 4
For the mesh configuration used, there was a total of 8855 domain elements, 1042 boundary elements,
and 143 edge elements. The corresponding element parameters are shown in Table 4. To verify selec-
tion of mesh that gives both an acceptable solution, and reduces unnecessary computation time, a mesh
convergence was performed, which is described in section 7.2 (Figure 5).
Table 4: Parameters of the mesh configuration used in COMSOL. The specified mesh configuration was
chosen based on a mesh convergence analysis (section 7.2).
Element Parameter Value
Maximum element size 0.0022 m
Minimum element size 3.96×10−4 m
Maximum element growth rate 1.5
Curvature factor 0.6
Resolution of narrow regions 0.5
From the mesh convergence in section 7.2, it was determined that the configuration shown in Table
4 is appropriate for the given problem; it limits spatial discretization error without taking up unnecessary
computation time.
7.2 Mesh Convergence
A mesh convergence was performed to verify that spatial discretization error is kept at minimum. Four
different mesh configurations (Figure 5) were implemented, and a plot of minimum concentration at the
posterior retina vs. time was generated for each mesh. From the mesh convergence analysis, it was deter-
mined that the mesh configuration specified in Table 4, as illustrated by the green line, has a solution that
converges with the dark blue line, which specifies a more refined mesh configuration.
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Figure 5: In this mesh convergence, the minimum concentration of drug at macular boundary was plotted
over time for four different mesh configurations.
Table 5: Abbreviations for mesh convergence configuration parameters
Abbreviation Parameter
max e Maximum element size
min e Minimum element size
growR Maximum element growth rate
ResCurv Curvature factor
ResNar Resolution of narrow regions
The mesh configuration specified by the green line was chosen because unlike the red or teal line, it
converges with the configuration specified by the dark blue line, which is for a finer mesh. Thus, the
configuration used should have a limited discretization error, without taking up too much computation time.
8 Results
To visualize the distribution of aflibercept in the vitreous humor at various times, surface plots of the
entire domain, as well as the macula boundary are shown.
Figure 6: Surface plot at t = 1 day. It appears that after 1 day, the distribution of drug is asymmetrical and
is dependent on the position of the injection site
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As seen in Figure 6, the distribution of drug as asymmetrical. There is more drug concentrated in
the vicinity of the injection sphere in comparison to the regions farthest from the injection sphere. This
asymmetry at early times exhibits the value of using a three-dimensional model, since a two-dimensional
axisymmetric model would not incorporate this slanted distribution of drug.
The typical time between injections of aflibercept is roughly 28 days. Therefore, a surface plot of
aflibercept distribution after 28 days has elapsed is shown in Figure 7. This plot will give a better under-
standing of both the distribution and amount of drug at a time when another injection is expected.
Figure 7: Surface plot at t = 28 days. Concentrations are virtually uniform at later times.
As seen in Figure 7, the distribution of drug is more symmetrical than the distribution of drug after 1 day
has elapsed. This is expected, since enough time has passed allowing a distribution closer to equilibrium
to be reached. However, it is also critical to note that there are very minute differences in concentration
between the regions where concentration is highest and where concentration is lowest. Taking into consid-
eration the scale of the surface plot shown in Figure 7, is clear that the minimum and maximum values are
very close to each other, demonstrating this uniformity after long times.
Next, plots of the macula boundary are shown. To reiterate, the macula boundary is a two-dimensional
slice of our model that is defined as a critical region of interest due to its proximity to the macula, the region
where damage due to blood vessel proliferation is most detrimental. This is the area where concentrations
of aflibercept should be adequately high, in order to inactivate appropriate amounts of VEGF.
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Figure 8: Surface plot of the macula boundary (see Figure 2 for exact location) at t = 1 day, which shows
aflibercept concentration is concentrated on one side due to the asymmetry of this problem
Once again, Figure 8 demonstrates the value of a 3D model at early times, due to its asymmetry. As
seen in the plot, there is a higher concentration of aflibercept on the left side in comparison to the right side,
due to the initial placement of the injection sphere a distance away from the central axis.
Figure 9, like Figure 7, shows that aflibercept distribution approaches equilibrium after 28 days, which
is the typical time between aflibercept injections.
Figure 9: Surface plot of the macula boundary (see Figure 2 for exact location) at t = 28 day, which shows
aflibercept concentration is roughly uniform after long times.
While the distribution appears symmetrical, it is once again important to note that the highest concen-
tration in the plot is virtually equivalent to the lowest concentration in the plot.
Next, a visualization for pressure-driven flow was generated in COMSOL.
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Figure 10: Velocity field in the vitreous humor due to pressure difference between the anterior hyaloid
membrane and the posterior retina
The velocity field shows the direction and magnitude of flow in the model, which is the basis for the
convective terms in the governing equations for both aflibercept and VEGF.
9 Validation
Validation for the model was done in terms of aflibercept half-life in the vitreous humor. Half-life is
defined as the time at which the amount of drug in the vitreous humor is half of the initial amount injected.
Since the initial concentration, in molm3 , is 0.34783, the initial amount of drug, in mol, is 1.73915 ·10−8 mol.
Thus, half-life is the time at which the total amount of drug in the vitreous humor is 8.69575 · 10−9 mol.
Taking into account the volume of the vitreous humor domain, the half life should occur when the average
concentration is 0.0015molm3 .
Figure 11: Plot of average concentration of aflibercept vs time. The time at which half of the total drug is
taken away from the domain is roughly 20 days.
According to literature, an appropriate half-life for aflibercept is within the range of 4.5 and 4.8 days
[3]. If the half-life in the model is within this range, then the model is roughly validated. The model showed
a half-life of about 20 days, which is notably greater than values found in literature, but sensible considering
that animal models were used to calculate shorter half lives while this model is intended for human eyes.
Therefore, longer half lives determined in this model (due to human metabolism being slower than rabbit
metabolism) are reasonable.
To validate this model further, concentrations of VEGF in the vitreous humor were observed (Figure
11). By taking into account the rate of change of VEGF at various times, as well as the typical amount of
time between aflibercept injections, a more sensible reasoning for the results can be achieved.
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Figure 12: Plot of average concentration of VEGF vs time.
Figure 12, which plots the average concentration of VEGF in the vitreous humor over time, made clear
that VEGF concentration drops significantly at early times as it binds to aflibercept and becomes inactivated
via complex formation. After 28 days elapsed, the rate of change of VEGF began to increase due to zeroth
order production, which is intuitive since it would be sensible to have another aflibercept injection if VEGF
concentration begins to rise again (since there is already VEGF overexpression).
9.1 Sensitivity Analysis
A sensitivity analysis on five selected input parameters was performed (Figure 13). The selected pa-
rameters were initial drug concentration, diffusion coefficient of the drug, viscosity of vitreous humor,
permeability of vitreous humor, and retinal clearance. A range approach was used, which involved chang-
ing each parameter of interest by ±10%. The effect on the result, which is the minimum concentration of
aflibercept at the macula boundary at 28 days, was observed for each parameter change. In a physical sense,
the only parameters that can be altered are the initial drug concentration and the diffusion coefficient of the
drug.
Figure 13: Sensitivity analysis for the following parameters: initial drug concentration, diffusion coefficient
of the drug, viscosity of vitreous humor, permeability of vitreous humor, and retinal clearance.
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The sensitivity analysis suggests that initial concentration of drug, and retinal clearance have the most
impact on minimum drug concentration at the macula boundary. Diffusion coefficient, permeability, and
viscosity have little to no impact.
10 Conclusions and Design Recommendations
The model described exhibits characteristics mirroring the intravitreal injection procedure. A three-
dimensional model was successfully constructed, which is a significant improvement over the two-dimensional
models and two-dimensional axisymmetric models commonly found in literature. With respect to more
specific results, it was found that asymmetric drug distributions were most apparent at early times in com-
parison to later times. At the macula boundary, this asymmetry was noted at earlier times too, where the
inital position of the injection sphere played a major role on the appearance of the surface plot. Validation
was achieved in two ways: by comparing half-life with values found in literature, and by noting the amount
of time between aflibercept injections while considering amounts of VEGF at various times. These com-
parisons assure that the model is computing concentrations with reasonable accuracy. Furthermore, it is
recommended that the time between aflibercept injections remain at 28 days.
Theoretically, the model could be utilized to model the transport of other drugs administered the same
way. Moreover, this study sheds light upon which input parameters influence the results the most. In this
study, it was found that these particular parameters were initial concentration and retinal clearance. The
model has important implications in the field of biotechnology as it can provide supporting data for drugs
in the clinical trial phase. Such models allow drug developers to gain insight regarding the behavior of
intravitreal drugs without having to spend as much money on physical experiments and additional research.
Ultimately, the usage of models similar to the one proposed in this study will lead to great savings and a
more comprehensive understanding of real-world problems.
Further improvements to this model that would result in potentially more accurate and realistic results.
One improvement could be the use of a more realistic geometry. This could be achieved by importing more
detailed meshes or scans, such as an MRI, from online databases. Another improvement that could be made
is including convection as a result of the injection process. Including the injection in the model as opposed
to an injection sphere with an initial concentration would be more realistic than the current model.
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Appendix
Appendix A: Input parameters.
Parameter Symbol Value Units Source
Anterior hyaloid membrane radius N/A 5.5 m [2]
Curvature factor ResCurv 0.6 N/A COMSOL
Diameter of macula N/A 5.5 m [13]
Distance between macula boundary and retina N/A 0.425 m [13]
Distance between limbus and injection site N/A 3.5 m [12]
Drug diffusion coefficient DA 5.556 ·10−10 m2s [5]
First order metabolism rate constant kA 149.26 ·10−9 1s [6]
Flux at hyaloid membrane N/A 0 molm2·s [5]
Flux at the retina boundary N/A R · cA molm2·s [5]
Initial drug concentration in injection site N/A 40 mgmL [1]
Initial drug concentration in injection site cAi 0.34783 molm3 [1]
Initial drug concentration in vitreous humor N/A 0 molm3 N/A
Initial pressure in vitreous humor N/A 15 Pa [5]
Initial VEGF concentration N/A 1.3122 ·10−7 molm3 [9]
Maximum element size max e 0.0022 m COMSOL
Maximum element growth rate growR 1.5 N/A COMSOL
Permeability in vitreous humor K 10 ·10−17 m2 [4]
Pressure at hyaloid membrane N/A 15.09375 Pa [5]
Pressure at vitreous humor N/A 14.90625 Pa [5]
Minimum element size min e 3.96 ·10−4 m COMSOL
Radius of spherical injection site rs 2.285 m [1]
Radius of vitreous humor N/A 11 m [2]
Resolution of narrow regions ResNar 0.5 N/A COMSOL
Retinal clearance R 1 ·10−9 ms [5]
Second order inactivation rate constant kV 410 ·10−5 1M·s [10]
VEGF diffusion coefficient DV 1.42 ·10−10 m2s [7]
Vitreous humor viscosity µ 1 ·10−3 Pa · s [5]
Zeroth order production rate constant kP 1.22 ·10−14 Ms [11]
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Appendix B. Computational time taken in an average run.
Figure 14: Computational time taken in an average run
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Figure 15: Team Responsibilities
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